🇺🇸 FDA

Drug profile · INN

liraglutide

SAXENDA

approved A10BJ02
US status
approved
Patents linked
3
News articles
0

Quick answer

liraglutide (SAXENDA) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: subcutaneous. Current US regulatory status: approved.

Key facts

INN liraglutide
Brand SAXENDA
Route SUBCUTANEOUS
Formulation SOLUTION
ATC code A10BJ02
Originator Teva Pharma GmbH

Related patents

Search patents →

  1. US 10851146

    Method for preparing liraglutide intermediate polypeptide

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9486414

    Method for delivering liraglutide preparations into a lumen of the intestinal tract using a swallowable drug delivery device

    Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8809271

    Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

    Expires Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is liraglutide?

liraglutide (SAXENDA) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: subcutaneous. Current US regulatory status: approved.

What is the brand name for liraglutide?

SAXENDA is a marketed brand name for liraglutide. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of liraglutide?

liraglutide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.